Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer

The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer discovery Ročník 5; číslo 9; s. 909
Hlavní autoři: Heideman, Marinus R, Frei, Anna, Hynes, Nancy E
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.09.2015
Témata:
Animals
Antineoplastic Agents, Hormonal - pharmacology
Drug Resistance, Neoplasm - genetics
Estrogen Receptor alpha - metabolism
Female
Gene Expression Regulation, Neoplastic
Homeodomain Proteins - metabolism
Humans
Receptor, ErbB-2 - metabolism
ISSN:2159-8290, 2159-8290
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.
AbstractList The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.
The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.
Author Heideman, Marinus R
Hynes, Nancy E
Frei, Anna
Author_xml – sequence: 1
  givenname: Marinus R
  surname: Heideman
  fullname: Heideman, Marinus R
  organization: Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
– sequence: 2
  givenname: Anna
  surname: Frei
  fullname: Frei, Anna
  organization: Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. University of Basel, Basel, Switzerland
– sequence: 3
  givenname: Nancy E
  surname: Hynes
  fullname: Hynes, Nancy E
  email: nancy.hynes@fmi.ch
  organization: Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. University of Basel, Basel, Switzerland. nancy.hynes@fmi.ch
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26334046$$D View this record in MEDLINE/PubMed
BookMark eNpNUN9LwzAYDDJxc-4_EMmjL93yo02aR9dNJ4wN5gTfStp-GZE2mU0n-t87cYrHwXfcHd_DXaKe8w4QuqZkTGmSThhNVJQyRcbZLKJJRFJJz9Dgz-790300CuGVHBGrOCHyAvWZ4DwmsRig1Va3O-is22GNV_4dajzfTBbrl6nET3bndP0dLb3fY-vwVjf-wxpw0QaCDZ12HZ62oEOHM-1KaK_QudF1gNHpDtHz_XybLaLl-uExu1tGJU94FxnNgFLJOK2ULBUhwCpTSVFoKYQ2JomNTEwJQhQVJYJwKCQvdcoVlBQKwobo9ufvvvVvBwhd3thQQl1rB_4QciqJOlJxcazenKqHooEq37e20e1n_rsB-wIlAWA9
CitedBy_id crossref_primary_10_3389_fcell_2021_697086
crossref_primary_10_1007_s12282_019_00980_5
crossref_primary_10_1096_fj_202301060RRR
crossref_primary_10_1016_j_lfs_2018_12_011
crossref_primary_10_1038_s41374_018_0150_4
ContentType Journal Article
Copyright 2015 American Association for Cancer Research.
Copyright_xml – notice: 2015 American Association for Cancer Research.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/2159-8290.CD-15-0871
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2159-8290
ExternalDocumentID 26334046
Genre Comment
Journal Article
GroupedDBID ---
53G
5VS
ADBBV
ADCOW
AENEX
AFHIN
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BR6
BTFSW
CGR
CUY
CVF
EBS
ECM
EIF
EJD
H13
KQ8
NPM
OK1
RCR
RHI
7X8
ID FETCH-LOGICAL-c353t-fa2e117231d97c900e2dfd76ba766aff54f75fce66bd10603eb73ca839ec1eb02
IEDL.DBID 7X8
ISICitedReferencesCount 6
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000360835200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2159-8290
IngestDate Fri Sep 05 08:50:36 EDT 2025
Thu Apr 03 07:06:13 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 9
Language English
License 2015 American Association for Cancer Research.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c353t-fa2e117231d97c900e2dfd76ba766aff54f75fce66bd10603eb73ca839ec1eb02
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
OpenAccessLink https://cancerdiscovery.aacrjournals.org/content/candisc/5/9/909.full.pdf
PMID 26334046
PQID 1709709936
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1709709936
pubmed_primary_26334046
PublicationCentury 2000
PublicationDate 2015-Sep
20150901
PublicationDateYYYYMMDD 2015-09-01
PublicationDate_xml – month: 09
  year: 2015
  text: 2015-Sep
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer discovery
PublicationTitleAlternate Cancer Discov
PublicationYear 2015
References 26180042 - Cancer Discov. 2015 Sep;5(9):944-59
References_xml – reference: 26180042 - Cancer Discov. 2015 Sep;5(9):944-59
SSID ssj0000494507
Score 2.1353588
Snippet The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 909
SubjectTerms Animals
Antineoplastic Agents, Hormonal - pharmacology
Drug Resistance, Neoplasm - genetics
Estrogen Receptor alpha - metabolism
Female
Gene Expression Regulation, Neoplastic
Homeodomain Proteins - metabolism
Humans
Receptor, ErbB-2 - metabolism
Title Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/26334046
https://www.proquest.com/docview/1709709936
Volume 5
WOSCitedRecordID wos000360835200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3w8ieI3bNG2SnkRXxYPWZV2htyVJE1nQdt2u4s930u2uJ0EQQg5pWsrkS-bLzCSD0JkRObdMRyTOmSCRlpwkgaMkkbmzJpJcK1cnmxBpKrMs6TQGt6oJq5yuifVCnZfG28hbVAQJlITxi-E78VmjvHe1SaExjxYZUBmPapHJmY3F330S1yemQbElxPsMm9NzNJatWdt5-5rQmARS0N95Zq1vbtf--6fraLVhmvhyAo0NNGeLTbT80PjSt1Daq4PAQXVhhdPy077im27r7jG7Evhp8OIJOjy6L8shHhS4p97Kr4GzBenaynPOYoyvfED7GLc9cEbb6Pn2pte-I012BWJYzMbEqdBSoC-M5okwSRDYMHe5gMERnCvn4siJ2BnLuc5h3xgwqwUzCgiVNdTqINxBC0VZ2D2EpTQR0JyQKssireALmkFnxzVTzAi2j06nkuoDer1LQhW2_Kj6P7LaR7sTcfeHk2s2-iFnLILt-8Ef3j5EK8Bk4knw1xFadDB37TFaMp_jQTU6qWEBddp5-AaZbMAW
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+a+Novel+ER%2FHOXB7+Signaling+Loop+in+Tamoxifen-Resistant+Breast+Cancer&rft.jtitle=Cancer+discovery&rft.au=Heideman%2C+Marinus+R&rft.au=Frei%2C+Anna&rft.au=Hynes%2C+Nancy+E&rft.date=2015-09-01&rft.issn=2159-8290&rft.eissn=2159-8290&rft.volume=5&rft.issue=9&rft.spage=909&rft_id=info:doi/10.1158%2F2159-8290.CD-15-0871&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2159-8290&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2159-8290&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2159-8290&client=summon